Amyloid β1-6 antigen arrays

Details Amyloid β1-6 antigen arrays Amyloid β1-6 antigen arrays

2007-10-09

2007-10-09

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S194100, C424S184100, C424S400000, C530S403000, C530S404000, C530S405000, C530S406000, C435S235100

Reexamination Certificate

active

10622087

ABSTRACT:
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5565548 (1996-10-01), Neurath et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5916818 (1999-06-01), Irsch et al.
patent: 5928647 (1999-07-01), Rock
patent: 5935821 (1999-08-01), Chatterjee et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6180771 (2001-01-01), Thomas et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6380364 (2002-04-01), Mueller et al.
patent: 6827937 (2004-12-01), Murray
patent: 6932971 (2005-08-01), Bachmann et al.
patent: 6964769 (2005-11-01), Sebbel et al.
patent: 7115266 (2006-10-01), Bachmann
patent: 7128911 (2006-10-01), Bachmann et al.
patent: 2002/0052311 (2002-05-01), Solomon et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0157479 (2003-08-01), Bachmann et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 2003/0219459 (2003-11-01), Bachmann et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 0 038 154 (1981-10-01), None
patent: 0 259 149 (1993-12-01), None
patent: 0 578 293 (1994-01-01), None
patent: 0 385 610 (1994-03-01), None
patent: WO 94/06472 (1994-03-01), None
patent: 0 465 081 (1994-04-01), None
patent: 0 283 505 (1994-07-01), None
patent: 0 425 082 (1995-04-01), None
patent: 09202735 (1997-08-01), None
patent: WO 90/15878 (1990-12-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 96/28624 (1998-07-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/28478 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/50461 (2000-08-01), None
patent: WO 00/59928 (2000-10-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/62284 (2001-08-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 01/53457 (2002-04-01), None
patent: WO 02/056905 (2002-07-01), None
patent: WO 02/056907 (2002-07-01), None
patent: WO 03/024480 (2003-03-01), None
Holtzman et al (2002) Advanced Drug Delivery Reviews 54: 1603-1613.
Bowie et al (1990) Science, 247 (4948): 1306-1310.
Frenkel et al (2000) PNAS, 97 (21): 11455-11459.
Vasiljeva et al (1998) FEBS Letters 431: 7-11.
Robinson and Sauer (1998) PNAS, 95: 5929-5934.
Golmohammadi et al (1996) Structure, 4: 543-554.
Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,”Virology170(1):238-242, Academic Press, Inc. (1989).
Ansel, K.M., et al., “A chemokine-driven positive feedback loop organizes lymphoid follicles,”Nature406(6793):309-314, Nature Publishing Group (2000).
Ansel, K.M., et al., “In Vivo-activated CD4 T Cells Upregulate CXC Cheomkine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines,”J. Exp. Med. 190(8):1123-1134, The Rockefeller University Press (1999).
Bachmann, M.F., and Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunology Today17(12):553-558, Elsevier Science Ltd. (1996).
Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).
Bachmann, M.F., et al., “Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes,”Eur. J. Immunol. 26(11):2595-2600, VCH Verlagsgesellschaft mbH (1996).
Bachmann, M.F., et al., “TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation,”J. Exp. Med. 189(7):1025-1031, The Rockefeller University Press (1999).
Bard, F. et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nat. Med. 6(8):916-919, Nature Publishing Company (2000).
Bass, S., and Yang, M., “Expressing cloned genes inEscherichia coli,” inProtein Function: A Practical Approach, 2nd ed., Creighton, T.E., ed., IRL Press, Oxford, Great Britain, 175:29-55, (1997).
Bowie, J.U., et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions.,”Science247(4948):1306-1310, (1990).
Brown, W.L., et al., “RNA bacteriophage capsid-mediated drug delivery and epitope presentation.,”Intervirology45(4-6):371-380, S. Karger AG Basel (2002).
Cesareni, G., “Peptide display on filamentous phage capsids: A new powerful tool to study protein-ligand interaction,”FEBS Lett. 307(1):66-70, Elsevier Science Publishers B.V. (1992).
Chackerian, B., et al., “Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles,”Proc Natl. Acad. Sci USA96(5):2373-2378, (1999).
Crameri, R. and Suter, M., “Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production,”Gene137(1):69-75, Elsevier Science Publishers B.V. (1993).
de la Cruz, V.F., et al., “Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage,”J. Biol. Chem. 263:4318-4322, The American Society for Biochemistry and Molecular Biology, Inc. (1988).
Dodart, J.-C., et al., “Immunotherapy for Alzheimer's disease: will vaccination work?,”TRENDS in Molecular Medicine9(3):85-87, (2003).
Donnelly, J.J., et al., “DNA Vaccines,”Annu. Rev. Immunol. 15:617-648, Annual Reviews, Inc. (1997).
Fehr, T., et al., “T cell-Independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles,”Proc. Natl. Acad. Sci95(16):9477-9481, (1998).
Fehr, T., et al., “Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies,”J

Affiliated with

Also associated with

Rating

Amyloid β1-6 antigen arrays does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amyloid β1-6 antigen arrays, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amyloid β1-6 antigen arrays will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3891911